Amplity executes 85% of business in oncology/specialty therapies; 60% of which is oncology. We work with 5 out of the top 5 global oncology companies and have access to 90% of oncology stakeholders in the US. Our team has deep expertise with over 50 companies, 100 drugs, and 20 tumor diagnostic launches across 11 tumor types.

Amplity has been an innovator of multiple “first time” programs for over 40 years. We are approved to operate in 40 countries across seven continents; with a proven track record in fully-compliant, custom global medical programs. Amplity has over 100 teams (medical and commercial) deployed globally, including more than 40 oncology brands.

Amplity owns a proprietary NLP longitudinal medical transcription database of oncology patients and providers as well as a stakeholder qualitative survey platform that can be leveraged throughout the lifecycle.

We have proprietary access to oncology care team networks through live and virtual events, and engagement through our family of journals.